Ignacio Duran
Hospital Universitario Marqués de Valdecilla
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ignacio Duran as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:28 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06133517 · PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder CancerFundación para el Progreso de la Oncología en Cantabria · active not recruiting · Urothelial Bladder Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:28 UTC. The ranking covers the 200 most relevant of 52 PubMed records, and a shared surname and initials can bring in a namesake. All 52 on PubMed
- 1,818 citationsRCR 57.2
- 1,141 citationsRCR 38.0
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.N Engl J Med · 20191,078 citationsRCR 40.4
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.N Engl J Med · 20211,062 citationsRCR 59.5
- 1,002 citationsRCR 130.6
- 654 citationsRCR 22.3
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.Nat Med · 2019497 citationsRCR 16.0
- 415 citationsRCR 15.5
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.Br J Cancer · 2006265 citationsRCR 6.2
- 230 citationsRCR 7.2